|
1
|
Joyce JA and Pollard JW:
Microenvironmental regulation of metastasis. Nat Rev Cancer.
9:239–252. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mroczko B, Groblewska M,
Wereszczynska-Siemiatkowska U, Okulczyk B, Kedra B, Laszewicz W,
Dabrowski A and Szmitkowski M: Serum macrophage-colony stimulating
factor levels in colorectal cancer patients correlate with lymph
node metastasis and poor prognosis. Clin Chim Acta. 380:208–212.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lukaszewicz-Zajac M, Mroczko B, Kozlowski
M, Niklinski J, Laudanski J and Szmitkowski M: Clinical
significance of serum macrophage-colony stimulating factor (M-CSF)
in esophageal cancer patients and its comparison with classical
tumor markers. Clin Chem Lab Med. 48:1467–1473. 2010. View Article : Google Scholar
|
|
4
|
Kowalska M, Kaminska J, Fuksiewicz M,
Kotowicz B, Chechlinska M, Druzd-Sitek A and Walewski J: A survey
of prognostic value of serum factors in multiple myeloma patients
before treatment: macrophage-colony stimulating factor (M-CSF) is a
powerful predictor of survival. Med Oncol. 28:194–198. 2011.
View Article : Google Scholar
|
|
5
|
Groblewska M, Mroczko B,
Wereszczynska-Siemiatkowska U, Mysliwiec P, Kedra B and Szmitkowski
M: Serum levels of granulocyte colony-stimulating factor (G-CSF)
and macrophage colony-stimulating factor (M-CSF) in pancreatic
cancer patients. Clin Chem Lab Med. 45:30–34. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ide H, Hatake K, Terado Y, Tsukino H,
Okegawa T, Nutahara K, Higashihara E and Horie S: Serum level of
colony-stimulating factor 1 as a marker of tumor progression in
prostate cancer patients. In: Hisamitsu Ide: Proceedings of the
American Association for Cancer Research Annual Meeting[C]. In:
96th Annual Meeting of the American Association for Cancer
Research; Anaheim, CA, USA. 2005; Tokyo, Japan: Kyorin Universiy;
47. pp. 7472005, PubMed/NCBI
|
|
7
|
Suzuki M, Ohwada M, Sato I and Nagatomo M:
Serum level of macrophage colony-stimulating factor as a marker for
gynecologic malignancies. Oncology. 52:128–133. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lawicki S, Omyla J, Mroczko B, Szmitkowski
M and Czygier M: Plasma level of macrophage-colony stimulating
factor (M-CSF) in the course of breast cancer treatment. Pol Arch
Med Wewn. 112:1181–1187. 2004.(In Polish).
|
|
9
|
Kuropkat C, Duenne AA, Herz U, Renz H and
Werner JA: Significant correlation of matrix metalloproteinase and
macrophage colony-stimulating factor serum concentrations in
patients with head and neck cancer. Neoplasma. 51:375–378.
2004.
|
|
10
|
National Comprehensive Cancer Network.
Gastric Cancer version v.1.2011. http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdfuri.
Accessed.
|
|
11
|
Mandorwski S, Lourenco LG and Forones NM:
CA72-4 and CEA in serum and peritoneal washing in gastric cancer.
Arq Gastroenterol. 39:17–21. 2002.(In Portuguese).
|
|
12
|
Dilege E, Mihmanli M, Demir U, Ozer K,
Bostanci O, Kaya C, Aksakal O and Sakiz D: Prognostic value of
preoperative CEA And CA 19-9 levels in resectable gastric cancer.
Hepatogastroenterology. 57:674–677. 2010.PubMed/NCBI
|
|
13
|
Zhu YB, Ge SH, Zhang LH, Wang XH, Xing XF,
Du H, Hu Y, Li YA, Jia YN, Lin Y, et al: Clinical value of serum
CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of
gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 15:161–164.
2012.(In Chinese).
|
|
14
|
Qian BZ and Pollard JW: Macrophage
diversity enhances tumor progression and metastasis. Cell.
141:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
